Dexcom Q3 2026 slides: margins hit multi-year high, guidance raised
Dexcom reported Q3 2026 revenue of $1.344B, up 11%, and record EPS of $0.73, exceeding expectations. Gross margins hit 65.1%, the highest since 2022, while guidance was raised. U.S. revenue grew 14%, but international growth slowed. Shares rose 1.73% after-hours.
How this was made
The 30-second read
Why it matters
The combination of beat results, record non-GAAP EPS, and raised full-year revenue and margin guidance creates a clear near-term repricing catalyst for DXCM, with follow-through dependent on continued G7 15 Day adoption and sustained gross margin gains.
Market read
Traders can update DXCM positioning based on the raised 2026 guidance ranges and the reported margin inflection in Q3.
What to watch
The guidance assumes continued margin progression despite Ireland facility ramp-up costs; any delay in manufacturing efficiencies or G7 15 Day rollout could temper the margin outlook.
Background
Dexcom’s Q3 2026 results emphasize profitability expansion alongside a guidance raise, with product mix and manufacturing efficiencies cited as key drivers.
Ticker impact
Dexcom raised full-year 2026 guidance and reported Q3 gross margin of 65.1%, the highest since late 2022, alongside record non-GAAP EPS.
Likely upward bias as the market prices in improved profitability trajectory and raised guidance for 2026.
The article reports both a margin inflection (65.1% gross margin) and explicit guidance increases for revenue and operating/EBITDA margins, which are direct earnings power inputs.
Market effects
Reinforces the MedTech/CGM theme that scale and product mix (G7 15 Day) can drive margin expansion even with moderating top-line growth.
Highlights stronger U.S. momentum versus slower international growth tied to reimbursement comparisons, which may influence regional demand expectations.
Limited direct global spillover beyond CGM competitive dynamics and reimbursement-driven adoption patterns.
Counterpoint
International growth is flat sequentially and management attributes it to reimbursement comparison effects, so investors may worry about underlying demand durability outside the U.S.
Key entities
- companyDexcom
NASDAQ-listed continuous glucose monitoring company reporting Q3 2026 results and raising full-year 2026 guidance.
- clinical_studyCONNECT study
Publication in The New England Journal of Medicine highlighting strong A1C results in randomized trials.
- productG7 15 Day
Extended-wear sensor rollout expected to reach nearly 50% of the U.S. customer base by year-end 2026.
- operationsIreland manufacturing facility
Ramp-up referenced as an incremental expense while operating margins expanded.
